[ad_1]
ALBANY, NY, Feb. 9, 2022 /PRNewswire/ — The global dyslipidemia drugs market was valued at US$ 11.8 Bn in 2018 and is anticipated to rise at a CAGR of 3.5% during the forecast period, from 2019 to 2027. The global dyslipidemia drugs market is likely to be driven by increasing awareness about illness through marketing activities and rising incidences of people with triglyceride and cholesterol abnormalities. Due to changes in lifestyle and other variables such as lack of exercise, obesity, and bad eating habits, the incidence of triglyceride and cholesterol imbalances is projected to rise dramatically globally.
Dyslipidemia is one of the most dangerous cardiovascular disorders, as per several government and corporate groups involved in the cholesterol medicine business. As of 2016, the Centers for Disease Control and Prevention (CDC) estimated that 95 million individuals (55% of the population) in the US had a total level of cholesterol higher than 200 mg/dL. In addition, an approximately 29 million adults in the US have a total level of cholesterol over 240 mg/dL. As a result, the global dyslipidemia drugs market is likely to be driven by a huge population base suffering from the disease during the forecast period.
Request Brochure of Dyslipidemia Drugs Market Research Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1535
The development of novel pharmaceuticals for the treatment of dyslipidemia as well as collaborations & collaborative contracts with other firms are among the top priorities of key competitors in the global dyslipidemia drugs market. These leading players’ approaches are anticipated to boost the global market. Players in the dyslipidemia drugs market have used a variety of expansion methods.
Key Findings of Market Report
- The global dyslipidemia drugs market is divided into bile acid resins, niacins, fibric acid, statins, and omega-3 fatty acid derivatives, and others based on drug class. Due to the supply or high sales of blockbuster drugs such as Crestor and Lipitor, the statins segment is likely to dominate the global dyslipidemia drugs market in the years to come.
- The global dyslipidemia drugs market has been divided into three distribution channels namely, retail pharmacies, hospital pharmacies, and …
Full story available on Benzinga.com
[ad_2]
Source link
